That's an excellent question. Thank you very much for that.
It's a complicated process. As I mentioned, there were two objectives. One was for readiness in case the virus were to evolve and we were to have human-human transmission, which would need a rapid response. Those are basically pandemic or pre-pandemic conditions. We were trying to balance that out and not wanting to procure vaccines for a large portion of the population. That's why we ended up going with that low number that would cover a maximum of 1% of the population. The second one was around the targeted use for at-risk populations.
It was never our assumption that we would get to a very high level of uptake because the primary purpose was readiness—just in case. That being said, we did learn from Finland, which is an example of a country that did modest deployment of vaccines for at-risk populations like veterinary workers and vets, wildlife workers, and lab workers working directly with the virus or working in areas where they're exposed to contaminated environments or animals.
We are taking our due diligence with our forward-looking approach. We are developing a new decision-making framework to guide on us on decisions for a future potential procurement of vaccines.